Delving Into Participation Trends in Renal Cell Carcinoma Studies
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Renal Cell Carcinoma. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Exploring Engagement Dynamics Among Individuals Impacted by Renal Cell Carcinoma
Overview
The study seeks to delve into the firsthand experiences of patients diagnosed with renal cell carcinoma who partake in a separate clinical study featuring a specific medical intervention. The primary emphasis will be on meticulously tracking the rates of trial completion and withdrawal among these individuals. By joining this clinical trial, individuals have the unique opportunity to contribute to the betterment of future renal cell carcinoma patients and play an active role in advancing clinical research.
Primary outcome measures
- Number of patients who decide to participate in a renal cell carcinoma clinical study [Time frame: 3 months]
- Rate of patients who remain in renal cell carcinoma clinical trial to trial completion [Time frame: 12 months]
Eligibility criteria
Inclusion criteria
- Patient has been diagnosed with renal cell carcinoma
- Patient is a minimum of 18 years or older
- Patient has self-identified as planning to enroll in a clinical study
Exclusion criteria
- Patient does not understand, sign, and return consent form
- Inability to perform regular electronic reporting
- Patient is pregnant
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Case-crossover
Study locations
United States · 1 center
- Power Life Sciences — San Francisco
Publications
- Petejova N, Martinek A. Renal cell carcinoma: Review of etiology, pathophysiology and risk factors. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2016 Jun;160(2):183-94. doi: 10.5507/bp.2015.050. Epub 2015 Nov 3. PMID 26558360
- Bakouny Z, El Zarif T, Dudani S, Connor Wells J, Gan CL, Donskov F, Shapiro J, Davis ID, Parnis F, Ravi P, Steinharter JA, Agarwal N, Alva A, Wood L, Kapoor A, Ruiz Morales JM, Kollmannsberger C, Beuselinck B, Xie W, Heng DYC, Choueiri TK. Upfront Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors or Targeted Therapy: An Observational Study from PMID 36272943
- Schmidinger M, Bamias A, Procopio G, Hawkins R, Sanchez AR, Vazquez S, Srihari N, Kalofonos H, Bono P, Pisal CB, Hirschberg Y, Dezzani L, Ahmad Q, Jonasch E; PRINCIPAL Study Group. Prospective Observational Study of Pazopanib in Patients with Advanced Renal Cell Carcinoma (PRINCIPAL Study). Oncologist. 2019 Apr;24(4):491-497. doi: 10.1634/theoncologist.2018-0787. Epub 2019 Mar 13. PMID 30867244
Identifiers
NCT: NCT06093568 · 74504682